MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Di
08 Maggio 2007 - 7:01PM
PR Newswire (US)
- Numax Achieves Primary Endpoint Among High-Risk Infants Versus
Current Standard of Care and Shows Reduction of Medically Attended
Outpatient RSV- Related Lower Respiratory Infections - TORONTO, May
8 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) today
announced positive results from a large prospective trial conducted
for prevention of respiratory syncytial virus (RSV). The trial
compared motavizumab, the investigational monoclonal antibody (MAb)
also known as Numax(R), with Synagis(R) (palivizumab), the standard
of care for preventing RSV hospitalization in high-risk infants. In
the Phase 3 study involving 6,635 pre-term infants at high risk for
RSV, with a primary endpoint of non- inferiority, motavizumab
demonstrated overall 26-percent fewer RSV hospitalizations compared
with Synagis (p
Grafico Azioni Medimmune (NASDAQ:MEDI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Medimmune (NASDAQ:MEDI)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Medimmune (MM) (NASDAQ): 0 articoli recenti
Più Medimmune (MM) Articoli Notizie